IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: These results suggest that IL-6 inhibitor, Tocilizumab and the CIGB-258, showed similar pattern of serum lipid profiles, but the TNF-α inhibitor (Infliximab) did not improve the lipid profile and hepatic inflammation, which were caused by the CML treatment in zebrafish.